$1.42
Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
Coherus to Participate in Upcoming Investor Conferences
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript
Overview
52-week range
$1.09
$2.62
22% of range
Avg surprise (last 3)
-17.2%
Avg reaction (last 2)
+8.3%
100% positive
Latest IV / EM
121%
EM ±24.1% · $2 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.13 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-0.27 | $-0.29 | +6.9% | +34.1% | +11.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.31 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.39 | $-0.25 | -56.0% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.41 | $-0.40 | -2.5% | — | +5.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.09 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.11 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.91 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.41 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.49 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.96 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $12M | — | $12M | $10M | $8M | — | $6M |
| Cost of revenue | $4M | $4M | — | $4M | $3M | $3M | — | $3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-32M | $-36M | — | $-44M | $-45M | $-45M | — | $-47M |
| Net income | $-21M | $-38M | — | $-36M | $298M | $-57M | — | $-11M |
| EPS (diluted) | $-0.13 | $-0.28 | — | $-0.31 | $2.57 | $2.57 | — | $-0.09 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $83M | $115M | $89M | $103M | $217M | $82M | $126M | $98M |
| Inventory | $6M | $5M | $3M | $2M | $5M | $4M | $4M | $48M |
| Total current assets | $134M | $206M | $207M | $461M | $380M | $310M | $342M | $369M |
| Total assets | $191M | $266M | $258M | $517M | $439M | $371M | $449M | $505M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $130M | $187M | $197M | $429M | $320M | $555M | $581M | $593M |
| Total equity | $61M | $79M | $61M | $88M | $120M | $-183M | $-132M | $-88M |